Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant 45 mg versus placebo in menopausal women with moderate to severe vasomotor symptoms who are unsuitable for hormone replacement therapy
NL-OMON52081Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Fezolinetant 45 mg with Placebo (2 arms). Primary endpoint: Mean change in frequency of moderate to severe vasomotor symptoms. Started Mar 2022; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NL-OMON52081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52081.